NCT05633199 is a NA clinical trial of cytoreductive surgery in Cytoreductive Surgery, sponsored by Women's Hospital School Of Medicine Zhejiang University.

Who is sponsoring NCT05633199?

NCT05633199 is sponsored by Women's Hospital School Of Medicine Zhejiang University.

What drugs are being tested in NCT05633199?

Interventions in NCT05633199: cytoreductive surgery.

What condition does NCT05633199 study?

NCT05633199 studies Cytoreductive Surgery.

Is NCT05633199 still recruiting?

NCT05633199 is currently not yet recruiting. Last updated 1 December 2022.

Last reviewed 2022-12-01 · How we verify

NCT05633199

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer

Not yet recruiting NA Last updated 1 December 2022

What this trial tests

NA trial testing cytoreductive surgery in Cytoreductive Surgery in 140 participants. Not yet recruiting.

Timeline

1 December 2022

Primary endpoint
1 November 2026

1 January 2028

Quick facts

Lead sponsor	Women's Hospital School Of Medicine Zhejiang University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	140
Start date	1 December 2022
Primary completion	1 November 2026
Estimated completion	1 January 2028
Sites	2 locations across China

Drugs / interventions tested

cytoreductive surgery

Conditions studied

Cytoreductive Surgery — all drugs for Cytoreductive Surgery →

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Who can join

Adults 18 to 70, female only, with Cytoreductive Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This novel study was specifically designed for platinum-resistant recurrent ovarian cancers with PFI\<6 months and aimed to compare prognosis of patients who received cytoreductive surgery followed by chemotherapy versus chemotherapy alone.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group.
Stiegeler N, Garsed DW, Au-Yeung G, Bowtell DDL, et al · · 2024 · cited 10× · PMID 38894867 · DOI 10.3389/fonc.2024.1387281
Platinum-resistant ovarian cancer in China: Practice and challenges.
Lin J, Li A, Liu L, Zhang L, et al · · 2026 · PMID 40908915 · DOI 10.1097/cm9.0000000000003763
Evaluation of secondary cytoreduction surgery in platinum-resistant ovarian cancer patients within three-line recurrent: a multicenter, randomized controlled study.
Chen T, Xu J, Xia B, Wang H, et al · · 2024 · PMID 37945326 · DOI 10.3802/jgo.2024.35.e22

Verify or expand the search:

Other trials of cytoreductive surgery

Trials testing the same drug.

NCT05610826 — Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver · Phase 1, PHASE2 · withdrawn
NCT03373058 — Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery · Phase 3 · unknown
NCT02399410 — Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis · Phase 2 · completed

Other recruiting trials for Cytoreductive Surgery

Currently open trials in the same condition.

NCT05597683 — Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy · NA · recruiting
NCT05316181 — CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER) · Phase 3 · active not recruiting

Other Women's Hospital School Of Medicine Zhejiang University trials

Trials by the same sponsor.

NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05633199 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
Last refreshed: 1 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05633199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing